A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia
Stopped The study was stopped due to operational feasibility and not due to any safety concerns
Conditions
- Chronic Phase Chronic Myeloid Leukemia
Interventions
- DRUG: Ponatinib 30 mg QD
- DRUG: Ponatinib 15 mg QD
- DRUG: Nilotinib 400 mg BID
Sponsor
Ariad Pharmaceuticals